| Study Short Title | Full Title | Name of PI | Dates | Status |
| BHIVA COVID-19 Registry | British HIV Association (BHIVA) COVID-19 Registry | Caroline Sabin | October 2020 - ongoing | Current |
| Association of HIV with outcomes of COVID-19 hospitalization outcomes | Outcomes of COVID-19-related hospitalization among people with HIV in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK) | Caroline Sabin | May 2020 - ongoing | Current |
| UK community survey of COVID/HIV | Community Survey of the experiences of COVID-19 on people living with HIV in the UK | Caroline Sabin | June 2020 - ongoing | Current |
| SIREN (Sarscov2 Immunity & REinfection EvaluatioN) | Impact of detectable anti-SARS-COV2 on the subsequent incidence of COVID-19 in healthcare workers | Alejandro Arenas-Pinto | September 2020 to September 2022 | Current |
| Analysing immune responses to vaccination | Analysing humoral and cellular immune responses to vaccination during chronic infection | Dimitra Peppa, Richard Gilson, Laura Waters | October 2020 to October 2025 | Recruiting |
| UKACH | UKACH Cohort for Acute Hepatitis C: A prospective, multicentre, observational, cohort study of Acute Hepatitis C in the United Kingdom | John Saunders | | Recruiting |
| ANTIMICROBIAL PROPHYLAXIS SURVEY (POPS) | Understanding the Prevelance of Prophylaxis for STI use among sexual health clinic users | John Saunders | | Recruiting |
| ASSIST | Assessing the impact of introducing online postal self-sampling for sexually transmitted infections into sexual health provision within the UK on health inequalities, access to care and clinical outcomes. | Fiona Burns & Jo Gibbs | 2st January 2021 to 31st March 2024 | Recruiting |
| Champions | Capturing Hepatitis C diagnoses Amongst MSM using Peer networks to Improve linkage to Services: Part 1 (Qualitative) | Nina Vora | | Recruiting |
| DEVA | | Richard Gilson | | Recruiting |
| EAGLE | | Richard Gilson | | Recruiting |
| Jenner II | Temporal analysis of host immune responses and mechanisms impairing control of viral replication of during the course of HIV-1 infection | Dimitra Peppa | | Recruiting |
| LEGACY | SARS-CoV-2 Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study) | Richard Gilson | | Recruiting |
| LAPTOP | An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease – The Late Presenter Treatment Optimisation Study (LAPTOP) | Robert Miller | | Recruiting |
| POPPY NEW WAVE | A prospective, observational study to examine the efects of ageing on the clinical outcomes of people living with HIV in England and Ireland - Waves 4 and 5 POPPY 4 & 5 - 'Pharmacokinetic and Clinical Observations in People over Fifty Waves 4 and 5' | Ian Williams | | Recruiting |
| POSITIVE VOICES | Positive Voices: The national survey of people living with HIV | Richard Gilson | | Recruiting |
| PREP DLM | Urine drug level monitoring (DLM) to support HIV pre-exposure prophylaxis (PrEP) adherence | John Saunders | | Recruiting |
| RIO | The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART | Sarah Pett | | Recruiting |
| SEQUENCE DIGITAL | SEQUENCE Digital - Sexual health equity through evidence-based online clinical care: Pre-Trial Qualitative Studies | John Saunders | | Recruiting |
| SEPAC | Screening and early detection to prevent anal cancer; development of a biomarker screening tool | Richard Gilson | April 2019 to March 2022 | Recruiting |
| INTUIT | Interaction Design for Trusted Sharing of Personal Health Data to Live Well with HIV | Jo Gibbs | | Closed for recruitment |
| Chips+ | CHIPS+: Optimising the health of young people with HIV in their transition from paediatric to adult care | Alistair Teague | | Closed for recruitment |
| POPPY | The POPPY (Pharmacokinetic and clinical Observations in PeoPle over fiftY) Study | Caroline Sabin | | Closed for recruitment |
| POPPY Sleep | POPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep pattern | Caroline Sabin | | Closed for recruitment |
| Mala Malini Hep B study | | Richard Gilson | | Ongoing |
| HIV Bioresource | | Fiona Burns | | Paused |
| Elite Controllers | HIV elite controllers: Comprehensive assessment of host factors associated with HIV-1 elite control | Dimitra Peppa | | Paused |
| B-SURE | A prospective, Multi-Centre Study (B-Sure) to evaluate long-term durability of sustained virologic response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have recieved and responsed to GSK3228836 in a previous treatment | Richard Gilson | | In follow up |
| DOLOMITE | DOLOMITE NEAT ID Network Study: A multi- site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women | Sherie Roedling | | In follow up |
| Eurosida 9 | EuroSIDA Cohort 9: Observational cohort study collecting clinical and demographic data for HIV-positive adults. | Simon Edwards | | In follow up |
| Eurosida 10 | EuroSIDA Cohort X: Observational cohort study collecting clinical and demographic data for coinfected HIV/HCV positive adults. | Simon Edwards | | In follow up |
| SAFETXT | Safetxt: randomised controlled trial of safer sex intervention delivered through mobile phone messaging | John Saunders | | In follow up |
| GSK EPI-HSV-006 | An epidemiologicaL study to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe. | John Saunders | | In follow up |
| MAVMET | MAVMET: a multicentre, 48 week randomised controlled factorial trial of adding Maraviroc and/or Metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy | Sarah Pett | | Completed |
| PETRAM | Understanding changes in treatment-related regional bone turnover using 18F-fluoride-PET/CT in HIV-1-infected men: PETRAM study | Sarah Pett | | Completed |
| SAFER (UCLH) | | Nina Vora | | Completed |
| PrEP IMPACT Trial | PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation. | Richard Gilson | | Completed |
| POPPY LIVER | Hepatic steatosis in people living with HIV older than 50 years of age: The POPPY Hepatic Steatosis Sub-Study | Alejandro Arenas-Pinto | | Completed |
| ECLEAR | Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR) | Erica Pool | | Completed |
| FLAIR | FLAIR: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy and Safety of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected ART-Naive Adult Participants | Sarah Pett | Nov 2016 - current | Completed |
| BESTT | BESTT WOMEN's STUDY: Bone Evaluation in HIV positive women who switch from Truvada/NNRTI to Triumeq | Laura Waters | May 2016 – Apr2020 | Completed |
| VITA | VITA: A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis | Richard Gilson | Nov 2017 – Jun 2019 | Completed |
| TANGO | A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically supressed | Sarah Pett | Apr 2018 - current | Completed |
| BRIDGE-IT | A randomised controlled trial to determine the effectiveness of bridging from emergency to regular contraception: The Bridge –it study | Richard Gilson | | Completed |
| DISCOVER | GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection | Richard Gilson | | Completed |
| PRIME FSH | PRIME Ovarian Biomarker Study: Biomarkers of ovarian ageing in postmenopausal women living with HIV - a prevalence study | Rob Miller/Shema Tariq | | Completed |
| START | Strategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 | Ian Williams | | Completed |
| PROUD | PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men | Richard Gilson | | Completed |
| River | RIVER - Research in Viral Eradication of HIV Reservoirs - a functional cure study | Sarah Pett | | Completed |
| H-ART 2 HEART | Deep Cardiovascular Phenotyping of People with HIV on Anti-Retroviral Therapy at risk of Heart Disease | Richard Gilson | | Completed |
| GENAFRICA | Genetic markers of kidney disease progression in people of African heritage in the UK CHIC cohort | Sarah Pett | | Completed |
| CIPHER | CIPHER - study of cognitive function in HIV+ people. | Lewis Haddow | | Completed |
| AMBER | AMBER - randomised, double-blind study to evaluate efficacy and safety of DRV/cobicistat/FTC/TAF vs. DRV/cobicistat fixed dose combination plus Truvada® | Laura Waters | | Completed |
| EMERALD | EMERALD: randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDF | Laura Waters | | Completed |
| FLU STUDY | Influenza acquisition in Health Care Workers who work on a dedicated influenza cohort ward | Richard Gilson | | Completed |
| STOP HCV-1 | STOP HCV-1: Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease. | Richard Gilson | | Completed |
| PARTNER | PARTNER 2.0: A study in HIV sero-different partnerships to estimate the rate of transmission of HIV and to investigate factors associated with condom use | Richard Gilson | | Completed |
| PIBIK | A Phase IV Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations | Laura Waters | | Completed |
| ICOS | International SARS-CoV-2 Infection Observational Study | Richard Gilson | 27th May 2020 - (ongoing) | Completed |
| GS-1489 | GS-US-380-1489: A phase 3, randomised, Double Blind Study to Evaluate the Safety and Efficacy of GS9883/FTC/TAF vs. Triumeq in HIV-1 Infected, Antiretroviral Treatment Naïve Adults | Laura Waters | | Completed |
| GS-1490 | GS-US-380-1490: A Phase 3, Randomised, Double Blind Study of the Safety and Efficacy of a Fixed Dose combination of GS9883/FTC/TAF vs. DOL/FTC/TAF in HIV-1 infected, Antiretroviral Treatment- Naïve Adults | Laura Waters | | Completed |
| Merck 021 | MK-1439A-021: Double-Blind, Randomised Trial of Safety and Efficacy of FDC of TDF/3TC/doravirine (MK1439A) Once Daily vs Atripla® in Treatment Naïve HIV-positives | Ian Williams | | Completed |
| Merck 024 | MK-1439A-024: randomised study evaluating immediate vs deferred switch to FDC of TDF/3TC/doravirine in patients stable and suppressed on a PI/r+2NRTI | Ian Williams | | Completed |
| Merck 018 | A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1Infected Subjects. | Ian Williams | | Completed |
| SALSA | A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed | Sarah Pett | | Completed |
| HIPVAC | HIPvac: Randomised controlled trial of Imiquimod cream vs. podophyllotoxin in combination with quadrivalent HPV or control vaccination in the treatment and prevention of recurrence of anogenital warts. | Richard Gilson | Feb 2014 - current | Completed |
| SYPHILIS TRANSCRIPTOMICS | Syphilis Transcriptomics: Proof of concept study that aims to utilise next generation sequencing and transcriptomic approaches to understand infection with Treponema pallidum | Patrick French | Oct 2017 - current | Completed |
| HPV SAMPLING | HPV Sampling Study: A study to evaluate the performance of human papillomavirus (HPV) DNA detection in residual specimens taken for Chlamydia trachomatis/Neisseria gonorrhoea nucleic acid amplification testing in men who have sex with men (MSM) | Diarmuid Nugent | Jan 2018 - current | Completed |
| PRIME | PRIME: Quantitative and qualitative study that will exploring the impact of the menopause on HIV-positive women's health and wellbeing | Shema Tariq | Jan 2016 – Oct 2017 | Completed |
| UK HDRD | UK HIV Drug Resistance Database | David Dunn | 2001 – current | Completed |
| GS-1823 | GS-US-292/1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects | Laura Waters | Sep 2016 – May 2018 | Completed |
| GS-1826 | GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years | Laura Waters | Aug 2016 – Mar 2018 | Completed |
| WISARD | AN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENTEXPERIENCED HIV-1 INFECTED SUBJECTS VIROLOGICALLY SUPPRESSED WITH NNRTIS RESISTANCE MUTATION K103N. | Laura Waters | | Completed |
| DOR-DOL | Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch | Laura Waters | | Upcoming |
| WEIGHT GAIN STUDY | | Alejandro Arenas-Pinto | | Upcoming |
| TREP-AB (SYPHILIS RCT) | Oral and Neuro-Penetrative Alternative Antibiotics for Patients with Syphilis | Richard Gilson | | Upcoming |
| TRANSBIC | Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH) | Laura Waters | | Upcoming |
| TINIES | Small Volume Blood Testing Validity and Acceptability for HIV-1 and Hepatitis B | Stuart Flanagan | September 2022 | Upcoming |
| STI Abbott | Development & Evaluation of CT/NG Rapid Tests | Richard Gilson | September 2022 | Upcoming |
| SPOTFIRE | POC test evaluation | Richard Gilson | September 2022 | Upcoming |
| SHINE | Sinecatechins in High grade Intraepithelial Neoplasia Eradication | Richard Gilson | April-2023 | Upcoming |
| SHIELD | Securing best health outcomes for people living with HIV through optimal engagement with care: Learning from Disruptive change | Laura Waters | | Upcoming |
| SEPAC patient experiences | | Emmi Suonpera | | Upcoming |
| SAFE ONE (BV Study) | Phase I study of a BV treatment | Richard Gilson | | Upcoming |
| REFINE-B | REgimen optimisation: Feasibility of sImplifying NucleotidE therapy in HIV/HBV coinfection | Stuart Flanagan | | Upcoming |
| PRIME Disability | The PRIME Disability Study | Shema Tariq | | Upcoming |
| PrEPaRe | Pre-exposure prophylaxis use in people newly diagnosed with HIV | Richard Gilson | | Upcoming |
| PrEP Quality of Life | PrEP Quality of Life | John Saunders | | Upcoming |
| OXFORD GC study | Ecology of oral Neisseria species in men who have sex with men: implications for Neisseria gonorrhoeae transmission and the emergence of antimicrobial resistance | Richard Gilson | | Upcoming |
| OTAC (INSIGHT) | An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 | Alejandro Arenas-Pinto | | Upcoming |
| MOSAIC | Cohort study in human Monkeypox virus disease | Alejandro Arenas-Pinto | | Upcoming |
| MISTRAL | Gut microbiome correlates of serious AIDS and non-AIDS events | Sarah Pett | September 2022 | Upcoming |
| META-D | Switch from stable cART containing ABA/3TC or TAF/FTC plus dolutegravir or bictegravir to TDF/3TC/doravirine in people living with HIV: Impact on lipids, body composition, insulin sensitivity, neuroendocrine function and inflammation markers | Alejandro Arenas-Pinto | | Upcoming |
| HIS-UK | Evaluating the Home-based Intervention Strategy (HIS-UK) to reduce new Chlamydia infection among young men aged 16-25 years by promoting correct and consistent condom use: What is the cost effectiveness of two different delivery models (face-to-face and digital delivery)? | Richard Gilson | | Upcoming |
| GSK HSV REC-003 | A study on the reactogenicity, safety, immune response, and efficacy of a vaccine against HSV-2 in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent HSV-2 genital herpes | John Saunders | | Upcoming |
| Gonorrhoea vaccine study (phase 3) | A Phase III, randomised, observer blind, placebo-controlled study to assess the efficacy of meningococcal combined ABCWY vaccine in preventing gonococcal infection in adolescents and adults 16 to 50 years of age. | Richard Gilson | | Upcoming |
| Gonorrhoea vaccine study (phase 1) | A Phase I/II, observer-blind, randomised, placebo controlled multi-country study to assess safety and efficacy of GSK NgG candidate vaccine when administered to healthy adults 18 to 50 years of age | Richard Gilson | | Upcoming |
| EBI-HIV | TBC | Shema Tariq | | Upcoming |
| CASCADE | Management of the current HIV epidemic in Europe: Important insights from HIV seroconverter cohorts | Kholoud Porter | | Upcoming |
| B-WELL | Multi-Centre, Randomised, Partial-Blind Parallel Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus on stable nucleos(t)ide treatment, or naïve patients not currently on nucleos(t)ide therapy | Richard Gilson | | Upcoming |
| Mgen | Feasibility of culture of Mycoplasma genitalium (MGen) from clinical specimens | John Saunders | | Upcoming |
| B-together | A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together) | Richard Gilson | | Upcoming |
Close